Lung cancer in patients with chronic obstructive pulmonary disease: Development and validation of the COPD lung cancer screening score

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 3, 2015, Pages 285-291

  De Torres, Juan P ^a   Wilson, David O ^b   Sanchez Salcedo, Pablo ^a   Weissfeld, Joel L ^b   Berto, Juan ^a   Campo, Arantzazu ^a   Alcaide, Ana B ^a   Garća Granero, Marta ^a   Celli, Bartolome R ^c   Zulueta, Javier J ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

COPD; Lung cancer; Screening

Indexed keywords

ADULT; ARTICLE; BODY MASS; CANCER RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; EMPHYSEMA; FAMILY HISTORY; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SMOKING; SPIROMETRY; ADVERSE EFFECTS; AGE DISTRIBUTION; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; EARLY CANCER DIAGNOSIS; EUROPE; FOLLOW UP; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MASS SCREENING; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; QUESTIONNAIRE; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX RATIO; UNITED STATES; VALIDATION STUDY;

ADULT; AGE DISTRIBUTION; AGED; EARLY DETECTION OF CANCER; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SMOKING; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84922311554     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201407-1210OC     Document Type: Article

References (37)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.
2. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986;105:503-507.
3. Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987;106:512-518.
4. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, et al.; ECLIPSE investigators. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008;31:869-873.
5. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
6. American Lung Association. Providing guidance on lung cancer screening to patients and physicians. 2012 Apr 23 [accessed 2013 Oct 17]. Available from: http://www.lung.org/lung-disease/lung-cancer/lung-cancer-screening-guidelines/lung-cancer-screening.pdf
7. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e78S-92S.
8. Jaklitsch MT, Jacobson FL, Austin JHM, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012;144:33-38.
9. Wender R, Fontham ETH, Barrera E Jr, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Gazelle GS, Kelsey DK, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin 2013;63:107-117.
10. Young RP, Hopkins RJ. Targeted CT image screening and its effect on lung cancer detection rate. Chest 2013;144:1419-1420.
11. Celli BR. Chronic obstructive pulmonary disease and lung cancer: common pathogenesis, shared clinical challenges. Proc Am Thorac Soc 2012;9:74-79.
12. de-Torres JP, Casanova C, Maŕn JM, Zagaceta J, Alcaide AB, Seijo LM, Campo A, Carrizo S, Montes U, Cordoba-Lanus E, et al. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir Med 2013;107:702-707.
13. Young RP, Hopkins RJ. Diagnosing COPD and targeted lung cancer screening. Eur Respir J 2012;40:1063-1064.
14. Young RP, Hopkins RJ. CT screening in COPD: impact on lung cancer mortality: de Torres JP, Casanova C, Marin JM et al. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir Med 2013; 107: 702-707. Respir Med 2014;108:813-814.
15. Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, Gardner HD, Sullivan R, Gamble GD. A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers. Postgrad Med J 2009;85:515-524.
16. Young RP, Hopkins RJ, Duan F, Deng X, Gamble GD, Chiles C, Aberle DH. Lung cancer susceptibility SNPs add to risk prediction score for lung cancer: a sub-analysis of the ACRIN-Biomarker arm of the NLST. Am J Respir Crit Care Med 2014;189:A5603.
17. Tammemögi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, Chaturvedi AK, Silvestri GA, Riley TL, Commins J, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013;368:728-736.
18. de Torres JP, Bastarrika G, Wisnivesky JP, Alcaide AB, Campo A, Seijo LM, Pueyo JC, Villanueva A, Lozano MD, Montes U, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007;132:1932-1938.
19. Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, Fisher SN, Wilson J, Leader JK, Siegfried JM, Shapiro SD, et al. Association of radiographic emphysema and airfl ow obstruction with lung cancer. Am J Respir Crit Care Med 2008;178:738-744.
20. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001;345:1075-1083.
21. Vestbo J, Hurd SS, Agustó AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
22. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
23. Bastarrika G, Wisnivesky JP, Pueyo JC, Díaz L, Arraiza M, Villanueva A, Alcaide AB, Campo A, Seijo L, de Torres JP, et al. Low-dose volumetric computed tomography for quantification of emphysema in asymptomatic smokers participating in an early lung cancer detection trial. J Thorac Imaging 2009;24:206-211.
24. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
25. Young RP, Hopkins RJ. Lung cancer risk prediction to select smokers for screening CT - letter. Cancer Prev Res (Phila) 2012;5:697-698, author reply 699.
26. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, Zakher B, Fu R, Slatore CG. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med 2013;159:411-420.
27. Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med 2012;157:571-573.
28. Wood DE, Eapen GA, Ettinger DS, Hou L, Jackman D, Kazerooni E, Klippenstein D, Lackner RP, Leard L, Leung AN, et al. Lung cancer screening. J Natl Compr Canc Netw 2012;10:240-265.
29. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, Silvestri GA, Chaturvedi AK, Katki HA. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-254.
30. Tammemagi MC, Lam SC, McWilliams AM, Sin DD. Incremental value of pulmonary function and sputum DNA image cytometry in lung cancer risk prediction. Cancer Prev Res (Phila) 2011;4:552-561.
31. Young RP, Hopkins RJ, Gamble GD, Etzel C, El-Zein R, Crapo JD. Genetic evidence linking lung cancer and COPD: a new perspective. Appl Clin Genet 2011;4:99-111.
32. Houghton AM, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. Nat Med 2008;14:1023-1024.
33. Rama I, Grinyó JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol 2010;6:511-519.
34. Bowman RV, Yang IA, Semmler AB, Fong KM. Epigenetics of lung cancer. Respirology 2006;11:355-365.
35. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245-1257.
36. de Torres JP, Maŕn JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, Baz-Dávila R, Zulueta JJ, Aguirre-Jaime A, Saetta M, et al. Lung cancer in patients with chronic obstructive pulmonary disease: incidence and predicting factors. Am J Respir Crit Care Med 2011;184:913-919.
37. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al.; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-161.